# Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)

> **NCT00821093** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1123 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** Indacaterol 150 µg
- **DRUG:** Salmeterol 50 µg
- **DRUG:** Placebo to indacaterol
- **DRUG:** Placebo to salmeterol

## Key facts

- **NCT ID:** NCT00821093
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 1123 (ACTUAL)
- **Last updated:** 2011-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00821093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00821093, "Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00821093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*